Valneva SE (VALN) Return on Equity (2022 - 2023)
Valneva SE's (VALN) quarterly Return on Equity came in at 0.01% in Q1 2023, little changed year-on-year from 0.01% in Q1 2022, and up 16.76% quarter-over-quarter from 0.01% in Q4 2022.
Valneva SE (VALN) Return on Equity (2022 - 2023) Analysis & Trends
Valneva SE has disclosed Return on Equity across 2 years of filings, most recently posting 0.01% for Q1 2023.
- Return on Equity for Q1 2023 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2023 was 0.01% (changed 0.0% YoY), and the FY2022 annual result was 0.01%, changed 0.0% from the prior year.
- Return on Equity came in at 0.01% for Q1 2023 at Valneva SE, up from 0.01% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.01% in Q3 2022 to a low of 0.01% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -0.81% |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -0.04% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 0.00% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -0.01% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -0.01% |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | 0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | 0.00% |